The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
LSE did a telephone interview with CJP - CEO of Proteome. LONDON (Alliance News) - Proteome Sciences PLC expects strong growth in the second half of 2013 with its contract sales side growing sharply, according to Chief Executive, Christopher Pearce. "Our contract sales side has been growing sharply [and] we expect to see that to continue. We will allow diagnostic companies to acquire some of our intellectual property for their own requirements. That will entail substantial royalties," Pearce told Alliance News in a telephone interview. "We expect strong growth in the second half of 2013," he added. Proteome Sciences, the drug company which studies proteins in order to identify and treat cancers and Alzheimer's disease earlier, is fresh from showing results at the HUPO congress in Japan, where it demonstrated products which it said show good results in identifying and treating Alzheimer's disease quicker. "HUPO is a major meeting, a coming together of academics and commercial players in the business. It's an important meeting to go and see what technological changes may be coming. We were simply able to announce two or three importantly new developments which we presented at the congress," Pearce told Alliance News. "In an ageing population, Alzheimer's disease is affecting everybody. At this point in time there are not any good therapeutics for the disease so diagnosis is usually too late. We have built up markers to identify and diagnose Alzheimers itself," Pearce said. "And by identifying the first signs of memory loss, we can diagnose the disease sooner," he added. Alzheimer's, which often goes undetected because symptoms are mistaken for natural signs of ageing, can cause memory loss, confusion or trouble with language. It is more common in elderly people. Proteome said it has discovered a product which can reduce the build up of proteins that are associated with the development of Alzheimer's. Due to the potential scope of this product, distribution is important; "We want the right pharmaceutical partner to take these licences on," Pearce said. Meanwhile, Proteome Sciences said another of its products is able to predict the likelihood of tumour recurrence in order to give personalised treatment to cancer patients. "We're a middleman, a pure research entity owning important intellectual property and will collect royalties as people pick up and use these things. We provide access to these technologies on an outsourcing basis to diagnostics companies and the proprietary ownership of the discoveries is protected by IP," Pearce said. Proteome's new cancer developments have so far commanded considerable interest from global commercial pharmaceuticals and diagnosticians, according to Pearce. Richard
Proteome Sciences presents data at HUPO By StockMarketWire | Wed, 18th September 2013 - 14:17 Proteome Sciences presented novel data and key assay developments at the HUPO 12th Annual World Congress in Japan. The data covered Tau in Alzheimer's disease, SysQuant in pancreatic cancer and a missing isoform in sugar structures of clusterin, a plasma protein biomarker for Alzheimer's in brain atrophy. Chief operating officer Dr. Ian Pike said: "We were delighted to be invited to the 12th HUPO congress to show results from the powerful biomarker services platform that we have developed from our TMT mass tags for customers where we are at the forefront in proteomics. "New assays for pTau and clusterin glycoprotein provide important additions to the range of assays and services that we offer our customers in Alzheimer's The added power delivered by SysQuant® identifies thousands of phosphorylation sites across key signalling pathways that give clinicians the ability for the first time to provide real time patient management, in this case in pancreas cancer. "These are exciting developments from proteomics that are fundamentally changing how clinicians identify and manage disease." At 2:17pm: (LON:PRM) Proteome Sciences share price was +0.75p at 46.75p
Thank you for the welcome, I was in PRM before when it went up to 70p but I sold out to early. I am back in now at 46p it seems to be moving from 40p to 45p so not a bad entry level. I have had a very good year made a lot of money on Builders I am in TEF started buying them at 45p they are now £3.10. I think PRM will pay big time 1 day but I am only looking for a quick in out if we have good RNS over the next few months.
I think cal will come good, will take a long time i was hopping for 50p last year. We need a div to move this share price. Hugh scott-barrett is doing a good job and i like the way he is pushing cal forward. I was in smp aswell a really good company i made good money on those shares but sold out before the really big rise. Sir stan lives near me so that is why i allways have smp on my watch list. Tef doing well the retrace in price is only profit taking, i did not buy a house from them yet : ) i think steph could be right we may see 3 in the future.
NOTIFICATION OF INTEREST DISCLOSURE PURSUANT TO SECTION DTR5 OF THE FSA DISCLOSURE & TRANSPARENCY RULES On 23 November 2012, the Company received notification that Henderson Global Investors has an interest in 31,931,140 Ordinary 1p shares in Capital & Regional plc. This represents 9.10% of the total voting rights of the Company. END